September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Preoperative use of a dexamethasone intravitreal implant as a perioperative anti-inflammatory strategy in uveitic cataract surgery
Author Affiliations & Notes
  • Hoang Mai LE
    Department of Ophthalmology, Pitié Salpétrière Hospital, Paris, France
  • Nathalie Butel
    Department of Ophthalmology, Pitié Salpétrière Hospital, Paris, France
  • Phuc LeHoang
    Department of Ophthalmology, Pitié Salpétrière Hospital, Paris, France
  • Bahram Bodaghi
    Department of Ophthalmology, Pitié Salpétrière Hospital, Paris, France
  • Footnotes
    Commercial Relationships   Hoang Mai LE, None; Nathalie Butel, None; Phuc LeHoang, None; Bahram Bodaghi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1888. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hoang Mai LE, Nathalie Butel, Phuc LeHoang, Bahram Bodaghi; Preoperative use of a dexamethasone intravitreal implant as a perioperative anti-inflammatory strategy in uveitic cataract surgery. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1888.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : To describe the outcome of preoperative use of a dexamethasone intravitreal sustained-release implant (0.7 mg) in patients with recurrent non infectious uveitis undergoing cataract surgery.

Methods : Retrospective cohort study. Data recorded from preoperative and post operative visits (1-week, 1-month, 6-month) included : type of uveitis, best corrected visual acuity (BCVA), intraocular pressure, clinical signs of intraocular inflammation, flare values measured by laser flare photometry and central macular thickness (CMT) evaluated by SD-OCT.

Results : 5 eyes of 5 patients with chronic recurrent non infectious uveitis were included. Ten days before cataract surgery, the dexamethasone implant was inserted into the vitreous. Preoperative mean BCVA was logMAR=0.9 improving to logMAR=0 one month after surgery, with a mean gain of 9 lines. The mean preoperative flare value was 13.6 ph/ms. One week and one month postoperatively, the mean flare values were 18.6 ph/ms and 15.7 ph/ms, respectively. Mean CMT as well as IOP remained stable 1 week, 1 month and 6 months postoperatively. No signs of flare-up nor adverse events were noted during the follow-up period.

Conclusions : Sustained-release dexamethasone (0.7 mg) intravitreal implant may be an effective treatment option for controlling intraocular inflammation after cataract surgery in patients with non infectious chronic recurrent uveitis. These preliminary data in a limited number of patients would warrant a more extensive prospective study comparing the efficacy of dexamethasone intravitreal implant to an alternative treatment regimen, in uveitic patients undergoing cataract surgery.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×